Cerebricon Ltd.

Preclinical proof of concept studies in animal models of CNS disease. Fully integrated in vitro and in vivo laboratories provide quick onset and high quality studies in Stroke, Parkinson's, Alzheimer's, Trauma, Migraine and Epilepsy. Internal research and development allows for the constant upgrading and re-engineering of models in order to maintain quality and reliability and applicability.

Activity:

- Contract Research
- Research & Development
- Other Industry Services

Product / Technology type(s) covered:

- Bio
- Cosmoceuticals
- Drug delivery
- NCE (new chemical entities)
- Pharmaceuticals / Therapeutics
- Phyto
- Nutritionals / Vitamins

Therapeutic targets:

- Aging
- Alzheimer's Disease
- Central nervous system
- Genetics
- Geriatrics
- Mental Health
- Neurology
- Pain
- Stroke

Markets Covered

a. HeadQuarter: Finland

b. Continent(s) active: Europe , North America , Far East

c. Countries active: UK, Germany, North America, France, Scandinavia, Japan

Corporate data:

Number of Employees: 15

Turnover:

Amount:	Year:	Currency:
850000	2003	Euro

Year founded: 2000